Aquestive Therapeutics Inc. (NASDAQ:AQST) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET
Company Participants
Bennett Watson - ICR Westwicke Investor Relations
Dan Barber - Chief Executive Officer
Ernie Toth - Chief Financial Officer
Carl Kraus - Chief Medical Officer
Stephen Wargacki - Chief Science Officer
Sherry Korczynski - Senior Vice President of Sales and Marketing
Conference Call Participants
Roanna Ruiz - Leerink Partners
David Amsellem - Piper Sandler
François Brisebois - Oppenheimer
Raghuram Selvaraju - H.C. Wainwright
Thomas Flaten - Lake Street Securities
Jason Butler - Citizens JMP
Gary Nachman - Raymond James
James Molloy - Alliance Global Partners
Operator
Good morning, and welcome to the Aquestive Therapeutics Second Quarter 2024 Conference Call. [Operator Instructions]
As a reminder, this call will be recorded. I would now like to introduce your host for today's conference call, Bennett Watson of ICR Westwicke Investor Relations. You may begin.
Bennett Watson
Thank you, operator. Good morning, and welcome to today's call. On today's call, I am joined by Dan Barber, Chief Executive Officer; and Ernie Toth, Chief Financial Officer, who are going to provide an overview of recent business developments and performance for the second quarter of 2024, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer; Dr. Stephen Wargacki, Chief Science Officer; and Sherry Korczynski, Senior Vice President of Sales and Marketing.
As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive’s website within the Investors section shortly following the conclusion of this call.
To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of second quarter 2024 results. A description of these measures along with a reconciliation to GAAP can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website.
During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language as outlined in yesterday's earnings release as well as the risks and uncertainties affecting the company as described in the Risk Factors section and in other sections included in the company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024.
As with any pharmaceutical company with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development, regulatory approval and commercialization of its product and other matters related to operations. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements. All forward-looking statements attributable to Aquestive or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday. The company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events or otherwise, except as required under applicable law.